bluebird bio
NEWS
Having a stock double in value is a good thing.
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Plenty of companies had interesting news to share at the J.P. Morgan Healthcare Conference in San Francisco this week, and bluebird bio received more attention than some.
As yet, the company has no products on the market, so the applications, if approved, would mark the company’s shift into a commercial company.
Juno Therapeutics is now the “cheapest” player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival Bluebird Bio.
bluebird bio stock has been on an upswing for most of the year, having recently taken a spike after positive news at the ASH Annual Meeting.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
Celgene and bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the ASH Annual Meeting.
These great biotech stocks to buy for the holidays come in all sizes -- small-cap, mid-cap, and large-cap.
JOBS
IN THE PRESS
CFO with proven track record will help lead transition to commercial company
The small size of sdAbs may enable the generation of more complex CAR T cell products such as those designed to combine additional functions into a single CAR molecule or recognize multiple tumor antigens simultaneously.
First presentation of data from patients with a β0/β0 genotype and a pediatric patient treated with LentiGlobin in Phase 3 Northstar-3 study both have stopped chronic blood transfusions
LentiGlobin treatment-derived hemoglobin HbAT87Q equals or exceeds sickling hemoglobin (HbS) levels in Group C patients at six months post treatment
bb21217 early safety profile consistent with CAR T platform therapies
bluebird bio, Inc. (Nasdaq: BLUE) announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).
Celgene Corporation and bluebird bio, Inc. today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma. bb2121 is being developed as part of a Co-Development, Co-Promote and Profit Share Agreement between Celgene and bluebird bio.
bluebird bio (Nasdaq: BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.m. ET at the Boston Harbor Hotel, Boston.
Company plans to pursue accelerated development pathway for LentiGlobinTM in sickle cell disease (SCD)
European Medicines Agency Will Evaluate LentiGlobin Marketing Authorization Application Under Accelerated Assessment